The nonclinical drug candidates that Akros Pharma takes into clinical development come out of the research conducted by Shionogi Takatsuki Research Center (STRC) of Shionogi. in Osaka, Japan. The current development focus for Akros reflects the research focus at STRC.
Currently, STRC and Akros are working to develop new therapeutics for the following disease states:
Code (Generic Name) |
Potential Indication |
Dosage form |
Mechanism |
Stage |
|
| JTE-051 |
|
Oral | Interleukin-2 inducible T cell kinase inhibitor | Suppresses overactive immune response via inhibition of the signal to activate T cells related to immune response. | Phase2 |
| JTT-662 |
|
Oral | SGLT1 inhibitor | Suppresses postprandial hyperglycemia and normalizes blood glucose level via inhibition of SGLT1. | Phase1 |
| JTT-861 |
|
Oral | PDHK inhibitor | Improves cardiac function by activation of pyruvate dehydrogenase (PDH) related to carbohydrate metabolism. | Phase2 |
| JTC-064 |
|
Oral | PDHK inhibitor | Improves metabolic abnormalities by activation of pyruvate dehydrogenase (PDH). | Phase1 |
| JTV-161 |
|
Oral | Pim-1 inhibitor | Suppresses pulmonary vascular cell proliferation by inhibiting Pim-1. | Phase1 |
| JTE-162 |
|
Oral | NLRP3 inhibitor | Suppresses immune response by inhibition of NLRP3 inflammasome | Phase1 |
| JTC-262 |
|
Oral | NLRP3 inhibitor | Suppress immune response by inhibition of NLRP3 inflammasome | Phase1 |
| JTV-263 |
|
Oral | H-PGDS inhibitor | Improve blood flow in ischemic lower extremities by inhibiting H-PGDS | Phase1 |
Clinical trial phase presented above is based on the first dose.